Clopidogrel nano-emulsion - Ascendia Pharmaceuticals
Alternative Names: ASD-002Latest Information Update: 27 Jun 2023
At a glance
- Originator Ascendia Pharmaceuticals
- Class 2 ring heterocyclic compounds; Antiplatelets; Chlorobenzenes; Esters; Pyridines; Small molecules; Thienopyridines
- Mechanism of Action Platelet ADP receptor antagonists; Platelet aggregation inhibitors; Purinergic P2 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Acute coronary syndromes
Most Recent Events
- 26 Jun 2023 FDA approves IND application for Clopidogrel nano-emulsion in coronary artery disease (CAD)
- 26 Jun 2023 Ascendia Pharmaceutical plans a phase I trial for coronary artery disease (IV)
- 28 Oct 2018 No recent reports of development identified for preclinical development in Acute coronary syndromes in USA (Parenteral, Injection)